POZEN Inc.  

(Public, NASDAQ:POZN)   Watch this stock  
Find more results for POZN
+0.21 (2.97%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.03 - 7.38
52 week 5.49 - 12.69
Open 7.10
Vol / Avg. 221,957.00/552,252.00
Mkt cap 231.74M
P/E     -
Div/yield     -
EPS -0.54
Shares 32.78M
Beta 1.56
Inst. own 68%
Nov 9, 2015
Q3 2015 POZEN Inc Earnings Call - Webcast
Nov 9, 2015
Q3 2015 POZEN Inc Earnings Release
Sep 29, 2015
POZEN Inc at Ladenburg Thalmann Life Sciences Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -140.02% 60.74%
Operating margin -140.77% 51.17%
EBITD margin - 51.23%
Return on average assets -72.25% 45.87%
Return on average equity -101.76% 60.98%
Employees 12 -
CDP Score - -


1414 Raleigh Rd Ste 400
CHAPEL HILL, NC 27517-8834
United States - Map
+1-919-9131030 (Phone)
+1-919-9131039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


POZEN Inc. (POZEN) is a pharmaceutical company. The Company has entered into a license agreement with Sanofi US, for the commercialization of PA8140 and PA32540, now known as YOSPRALA 81/40 and 325/40 (aspirin / omeprazole delayed release tablets). The Company has developed Treximet in collaboration with GlaxoSmithKline (GSK). Treximet has been approved by the FDA for the acute treatment of migraine attacks with or without aura in adults. The Company has developed VIMOVO with AstraZeneca AB (AstraZeneca). VIMOVO is the brand name for a fixed dose combination of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen in a single tablet. The Company is developing a combination of a PPI and aspirin in a single tablet intended to induce fewer gastrointestinal complications compared to an aspirin taken alone in patients at risk for developing aspirin associated gastric ulcers.

Officers and directors

Arthur S. Kirsch Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Andrew I. Koven President, Chief Business Officer
Age: 56
Bio & Compensation  - Reuters
Adrian Adams Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
William L. Hodges CPA Chief Financial Officer
Age: 60
Bio & Compensation  - Reuters
Jennifer L. Armstrong Executive Vice President - Human Resources
Age: 45
Bio & Compensation  - Reuters
Scott Charles Senior Vice President - Finance
Bio & Compensation  - Reuters
Gilda M. Thomas J.D. Senior Vice President, General Counsel
Age: 60
Bio & Compensation  - Reuters
Dennis L. McNamara Senior Vice President, Chief Business Officer
Age: 42
Bio & Compensation  - Reuters
John E. Barnhardt CPA Vice President - Finance and Administration
Age: 65
Bio & Compensation  - Reuters
Mark A. Glickman Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters